CoChat

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Shao, Wenlin, Mishina, Yuji M., Feng, Yun, Caponigro, Giordano, Cooke, Vesselina G., Rivera, Stacy, Wang, Yingyun, Shen, Fang, Korn, Joshua M., Mathews Griner, Lesley A., Nishiguchi, Gisele, Rico, Alice, Tellew, John, Haling, Jacob R., Aversa, Robert, Polyakov, Valery, Zang, Richard, Hekmat-Nejad, Mohammad, Amiri, Payman, Singh, Mallika, Keen, Nicholas, Dillon, Michael P., Lees, Emma, Ramurthy, Savithri, Sellers, William R., Stuart, Darrin D. · 2018 · Cancer Research
Cited by 44

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the activated BRAF oncogene. Here, we report antitumor properties of RAF709, a novel ATP-competitive kinase inhibitor with high potency and selectivity against RAF kinases. RAF709 exhibited a mode of RAF inhibition distinct from RAF monomer inhibitors such as vemurafenib, showing equal activity against both RAF monomers and dimers. As a result, RAF709 inhibited MAPK signaling activity in tumor models harboring either BRAFV600 alterations or mutant N- and KRAS-driven signaling, with minimal paradoxical activation of wild-type RAF. In cell lines and murine xenograft models, RAF709 demonstrated selective antitumor activity in tumor cells harboring BRAF or RAS mutations compared with cells with wild-type BRAF and RAS genes. RAF709 demonstrated a direct pharmacokinetic/pharmacodynamic relationship in in vivo tumor models harboring KRAS mutation. Furthermore, RAF709 elicited regression of primary human tumor–derived xenograft models with BRAF, NRAS, or KRAS mutations with excellent tolerability. Our results support further development of inhibitors like RAF709, which represents a next-generation RAF inhibitor with unique biochemical and cellular properties that enables antitumor activities in RAS-mutant tumors. Significance: In an effort to develop RAF inhibitors with the appropriate pharmacological properties to treat RAS mutant tumors, RAF709, a compound with potency, selectivity, and in vivo properties, was developed that will allow preclinical therapeutic hypothesis testing, but also provide an excellent probe to further unravel the complexities of RAF kinase signaling. Cancer Res; 78(6); 1537–48. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-17-2033

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 44

Metadata

Authors
Shao, W., Mishina, Y. M., Feng, Y., Caponigro, G., Cooke, V. G., Rivera, S., Wang, Y., Shen, F., Korn, J. M., Mathews Griner, L. A., Nishiguchi, G., Rico, A., Tellew, J., Haling, J. R., Aversa, R., Polyakov, V., Zang, R., Hekmat-Nejad, M., Amiri, P., Singh, M., Keen, N., Dillon, M. P., Lees, E., Ramurthy, S., Sellers, W. R., & Stuart, D. D.
Venue
Cancer Research
Published
2018-03-14
Volume
78
Issue
6
Pages
1537-1548
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2793233777
Cited by
44
References
14
FWCI
1.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-2033
The paper
Shao, W., Mishina, Y. M., Feng, Y., Caponigro, G., Cooke, V. G., Rivera, S., Wang, Y., Shen, F., Korn, J. M., Mathews Griner, L. A., Nishiguchi, G., Rico, A., Tellew, J., Haling, J. R., Aversa, R., Polyakov, V., Zang, R., Hekmat-Nejad, M., Amiri, P., . . . Stuart, D. D. (2018). Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-2033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.